Keywords non-small-cell lung cancer KRASG12C mTORC1 ERK Get full text access Log in, subscribe or purchase for full access. References 1. Lim, T.K.H. ... KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing Lung Cancer. 2023; 184, 107293 2. Liu, J. ... The KRAS-G12C inhibitor: activity and resistance Cancer Gene Ther. 2022; 29:875-878 3. Janne, P.A. ... Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation N. Engl. J. Med. 2022; 387:120-131 4. Skoulidis, F. ...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Antonios N. Gargalionis
Targeting the Epigenetic Landscape for Lung Cancer Treatment
The term ‘epigenetics’ was introduced in 1942 by embryologist Conrad Waddington [1]. However, it was not until the early 21st century that the concept began to attract widespread attention. The field reached a pivotal moment in 2022 when Douglas Hanahan identified epigenetic alterations as a fundamental hallmark of cancer, emphasising their critical contribution to tumour development and progression [2].
Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Biomarkers in Cerebrospinal Fluid for the Diagnosis and Monitoring of Gliomas
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Runx2 and Polycystins in Bone Mechanotransduction: Challenges for Therapeutic Opportunities
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Mechanotransduction Circuits in Human Pathobiology
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Special Issue “mTOR Signaling: Recent Progress”
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The potential of BRD4 inhibition in tumour mechanosignaling
It is broadly acknowledged that physical properties of cancer cells play a crucial role in all aspects of tumour development, from cancer initiation to malignant progression. Aberrant mechanical forces shape a dynamic interplay between tumour cells, extracellular matrix (ECM) and cells of the tumour microenvironment to promote cancer cell proliferation, invasion, metastasis and drug resistance.
Are YAP and TAZ valid prognostic signatures for NSCLC patients?
To the Editor, It is well established that cancer cell biomechanics represents an important factor engaged in non-small cell lung cancer (NSCLC) development and progression. Mechanosensor proteins mediate an interplay between cancer cells, alterations of the extracellular matrix (ECM) stiffness occurring during tumour expansion and cells from the tumour microenvironment (TME).
Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
Abstract : Mechanistic target of the rapamycin (mTOR) signaling pathway represents a central cellular kinase that controls cell survival and metabolism. Increased mTOR activation, along with upregulation of respective upstream and downstream signaling components, have been established as oncogenic features in cancer cells in various tumor types. Nevertheless, mTOR pathway therapeutic targeting has been proven to be quite challenging in various clinical settings.
Exosomes as Novel Diagnostic Biomarkers and Therapeutic Tools in Gliomas
Abstract : Exosomes constitute small extracellular vesicles that contain lipids, proteins, nucleic acids, and glycoconjugates from the secreted cells and are capable of transmitting signals between cells and coordinating cellular communication. By this means, they are ultimately involved in physiology and disease, including development, homeostasis, and immune system regulation, as well as contributing to tumor progression and neurodegenerative diseases pathology.
Targeting the YAP/TAZ mechanotransducers in solid tumour therapeutics
Extracellular matrix (ECM) interacts with solid tumour cells and cells from the tumour microenvironment (ΤΜΕ). Components of the ECM and various types of mechanical forces which are generated from ECM stiffening modulate properties of solid tumour cells, thereby affecting tumour proliferation, migration, angiogenesis, immune evasion, stemness and resistance to treatment.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Antonios N.
Contact Antonios N., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack